Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd (ENLV) is a clinical-stage biopharmaceutical company pioneering macrophage-reprogramming therapies through its lead candidate Allocetra. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments across its pipeline targeting immune dysregulation.
Access primary-source ENLV news including clinical trial results, research collaborations, and regulatory filings related to Allocetra's development in sepsis, osteoarthritis, and autoimmune conditions. Our curated news collection enables efficient tracking of the company's progress in creating off-the-shelf cell therapies designed to restore immune homeostasis.
Key updates include advancements in Phase I/II trials, manufacturing partnerships, and peer-reviewed data publications. Bookmark this page for direct access to ENLV's official press releases and objective third-party analysis of their innovative approach to immune rebalancing therapies.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced a new patent from the China National Intellectual Property Administration for its immunotherapy product, AllocetraTM. This patent strengthens the Company's intellectual property rights in China by covering methods, uses, and pharmaceutical compositions associated with AllocetraTM, aimed at treating life-threatening conditions such as sepsis and COVID-19. Enlivex focuses on developing immunotherapies for unmet medical needs, particularly in organ dysfunction and cancer therapies.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced positive interim results from its Phase II clinical trial of AllocetraTM in severe and critical COVID-19 patients. Out of eight treated patients, seven fully recovered and were discharged within an average of 4.7 days, while one patient improved from critical to moderate/severe. The treatment was well tolerated with no serious adverse events reported. The trial is part of a multi-center study aimed at evaluating AllocetraTM alongside standard care for the target patient population.
Enlivex Therapeutics has announced a positive clinical outcome for a 70-year-old patient with erosive osteoarthritis treated with Allocetra™. After five weekly infusions, the patient showed significant improvement, including a 93% reduction in CRP levels and no need for re-hospitalization over 24 months. This case marks a notable achievement in treating a rare disease with no effective options. Allocetra™ is also undergoing clinical studies for other conditions, including COVID-19.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the appointment of Dr. Brian Schwartz to its Board of Directors, effective November 15, 2020. Dr. Schwartz previously served as Chief Medical Officer at ArQule, leading its R&D until its $2.7 billion acquisition by Merck in February 2020. He expressed optimism about Enlivex’s AllocetraTM program, which is in clinical trials for sepsis and COVID-19, indicating strong potential for significant impacts on high-mortality diseases. Shai Novik, Executive Chairman, welcomed Dr. Schwartz's extensive experience in product development, which is expected to enhance shareholder value.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) will present its clinical development schedule for Sepsis, COVID-19, and Solid Cancer during a fireside chat at H.C. Wainwright’s 6th Annual Israel Conference on November 12, 2020. The Phase IIb trial for sepsis patients is set for Q4 2020, expecting 160 patient enrollments with interim results anticipated in Q3 2021. The ongoing COVID-19 Phase II trial will provide interim results by year-end 2020. Enlivex is also pursuing collaborations for solid cancer therapies, focusing on unmet medical needs in immune system rebalancing.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent on Allocetra™, its immunotherapy product. This patent covers treatment methods for autoimmune and inflammatory diseases like gout and Crohn’s disease. Enlivex aims to utilize Allocetra™ for life-threatening conditions with no effective treatments, including sepsis and COVID-19. CEO Oren Hershkovitz expressed optimism about Allocetra™'s potential in immune rebalancing, highlighted by preclinical data supporting its applicability.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has received authorization from the Israeli Ministry of Health to start a Phase IIb clinical trial for Allocetra™ in sepsis patients. This multi-center, placebo-controlled trial aims to enroll up to 160 patients, assessing safety, tolerability, and efficacy over 28 days. The company previously reported impressive Phase Ib results, showing zero mortality in Allocetra™-treated patients compared to 27% in controls. Allocetra™ has also been evaluated for COVID-19 treatment, with recent Phase Ib results indicating positive outcomes for five patients.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has announced a Key Opinion Leader webinar on November 5, 2020, focusing on COVID-19 treatment options, featuring Dr. Carlos Cordon-Cardo from Mount Sinai hospital. The session will discuss findings from over 68,000 COVID-19 patients and the potential of Allocetra™ as a treatment for severe cases. Recent Phase Ib trial results show that all five patients treated with Allocetra™ recovered. A Phase II trial is underway to further evaluate Allocetra™ in combination with standard care for 24 patients. No severe adverse events were reported.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the dosing of the first two patients in a Phase II clinical trial of Allocetra for severe and critical COVID-19 patients. This multi-center study aims to recruit up to twenty-four patients to evaluate Allocetra alongside standard care, focusing on safety, tolerability, and efficacy. The trial follows a successful Phase Ib trial where all five patients recovered. No severe adverse events were reported. The trial will observe patients for 28 days post-administration.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Israeli Ministry of Health has authorized a Phase II clinical trial for AllocetraTM targeting severe and critical COVID-19 patients. The trial aims to evaluate safety and efficacy, recruiting up to 24 patients. This follows positive results from a Phase Ib trial where all five treated patients recovered. Further details will be submitted to expedite regulatory review. The Phase Ib trial showed no severe adverse events, indicating a favorable safety profile for AllocetraTM.
